Natera (NTRA) Receives Media Sentiment Rating of 0.12

News coverage about Natera (NASDAQ:NTRA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Natera earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.6445675513966 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:NTRA traded down $0.15 during midday trading on Monday, hitting $9.12. 48,965 shares of the stock traded hands, compared to its average volume of 130,368. The company has a market cap of $501.80, a price-to-earnings ratio of -3.79 and a beta of 2.09. The company has a current ratio of 1.37, a quick ratio of 1.29 and a debt-to-equity ratio of -7.05. Natera has a one year low of $7.35 and a one year high of $14.76.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, March 13th. The medical research company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.27). The firm had revenue of $53.80 million for the quarter, compared to the consensus estimate of $56.83 million. Natera had a negative net margin of 64.61% and a negative return on equity of 357.12%. research analysts forecast that Natera will post -1.85 EPS for the current fiscal year.

Several brokerages have recently commented on NTRA. BidaskClub raised shares of Natera from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 20th. Zacks Investment Research downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd. Finally, Cowen reaffirmed a “buy” rating and set a $12.00 price objective on shares of Natera in a research note on Thursday, December 21st. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $14.50.

COPYRIGHT VIOLATION WARNING: “Natera (NTRA) Receives Media Sentiment Rating of 0.12” was originally posted by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with's FREE daily email newsletter.

Leave a Reply